Boston Scientific Posts $5.44B Q2 Revenue, Up 7.5% YoY as Profit Also Beats Estimates
Boston Scientific reported second-quarter 2026 revenue of $5.442 billion, up 7.5% year-over-year. Adjusted EPS of $0.86 also came in above the high end of the company's own guidance.
- Boston Scientific posted $5.44B in Q2 2026 revenue, up 7.5% year-over-year
- Adjusted EPS of $0.86 beat estimates, but full-year guidance was cut
Boston Scientific posted $5.442 billion in second-quarter 2026 revenue, beating market expectations, according to an SEC Form 8-K filing.
📊 Price at Time of Writing (July 29, 2026, 21:07 KST)
$46.06 ▲ +1.21%
≈ ₩66,695 (rate: 1,448)
Q2 Earnings at a Glance
Boston Scientific's second-quarter revenue rose 7.5% year-over-year, landing at the high end of the company's guided range of 5.5% to 7.5%. Net income also increased to $907 million, up from $797 million a year earlier. During the quarter, the company completed a $2 billion share buyback program and invested $1.5 billion in cardiac device maker MiRus, acquiring roughly a 34% stake.
- Revenue: $5.442 billion, up 7.5% year-over-year
- Adjusted EPS: $0.86, above the high end of the company's own guidance of $0.82–$0.84
- Net income: $907 million, up from $797 million a year earlier
Next-Quarter Outlook
The company expects third-quarter 2026 revenue to grow 3% to 5% year-over-year on a reported basis. For the full year, it projects reported revenue growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32. CEO Mike Mahoney said, "Our team delivered solid results this quarter despite a dynamic environment," adding that the company remains "confident in our long-term growth as we focus investment on our highest-performing businesses."
Market Reaction
As of 9:07 p.m. KST on July 29, 2026, Boston Scientific shares traded at $46.06, up 1.21% from the previous close. Investing.com reported that the results beat market expectations, with EPS coming in $0.03 above estimates and revenue also topping forecasts. However, the Wall Street Journal reported that the company lowered its earnings outlook ahead of a restructuring. MassDevice likewise noted that despite beating second-quarter estimates, the company once again trimmed its full-year 2026 guidance.
Segment Breakdown
- Cardiovascular segment: $3.624 billion, up 8.3% year-over-year
- MedSurg segment (Endoscopy, Urology, Neuromodulation): $1.818 billion, up 5.9% year-over-year
- — Endoscopy: $793 million, up 7.6%
- — Urology: $684 million, up 1.1%
- — Neuromodulation: $341 million, up 12.7%
This article was automatically generated based on the original SEC Form 8-K filing and news reports, with the goal of quickly conveying key data immediately after the announcement. Readers are advised to review the company's official filing before making trading decisions. The stock price reflects the time of writing and may differ from the current price.
BSXFrequently Asked Questions
What kind of company is Boston Scientific?
It's a U.S. medical device maker focused on cardiovascular, urology, and neuromodulation products. The company trades on the New York Stock Exchange (NYSE), not Nasdaq, under the ticker BSX.
What does 'adjusted earnings per share (EPS)' mean?
It's earnings per share calculated after excluding one-time costs or gains. The metric is used to compare a company's recurring, underlying business performance.
Results beat expectations, so why was guidance lowered?
Second-quarter revenue and profit both topped the company's targets. However, media reports say the company nonetheless lowered its full-year revenue and profit outlook.
What's the outlook for next quarter?
The company expects third-quarter 2026 revenue to grow 3% to 5% year-over-year on a reported basis. For the full year, it projects revenue growth of 5.5% to 6.5% and adjusted EPS of $3.28 to $3.32.
Wall Street's Defining Moments
See more
Smart Money Briefing
Weekly summaries of Wall Street guru moves and crypto whale activity.
